Administration Intravesical BCG Vaccine/therapeutic use Humans Neoplasm Recurrence Local/prevention & control Network Meta-Analysis *Urinary Bladder Neoplasms/drug therapy/pathology Bladder cancer Intermediate risk Intravesical therapy Non–muscle-invasive bladder cancer

Cystectomy Humans Lasers Neoplasm Recurrence Local/surgery *Urinary Bladder Neoplasms/radiotherapy/surgery Urologic Surgical Procedures Bladder cancer Laser surgery Transurethral resection

Cystoscopy Fluorescence Recurrence rate Recurrence-free survival Urinary bladder neoplasms

Adult Aged Aged 80 and over Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use B7-H1 Antigen/antagonists & inhibitors Carcinoma/*drug therapy/immunology/mortality/pathology Clinical Decision-Making Female Humans Immune Checkpoint Inhibitors/adverse effects/*therapeutic use Male Middle Aged Patient Selection Progression-Free Survival Time Factors Urinary Bladder Neoplasms/*drug therapy/immunology/mortality/pathology Urothelium/*drug effects/immunology/pathology Immune-checkpoint inhibitor Meta-analysis Programmed death-ligand 1 Urothelial carcinoma interests/personal relationships which may be considered as potential competing interests: The authors certify that all conflicts of interest including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the article are listed as follows: Shahrokh Shariat owns or co-owns the following patents: methods to determine prognosis after therapy for prostate cancer. Granted 2002-09-06. Methods to determine prognosis after therapy for bladder cancer. Granted 2003-06-19. Prognostic methods for patients with prostatic disease. Granted 2004-08-05. Soluble Fas: urinary marker for the detection of bladder transitional cell carcinoma. Granted 2010-07-20. He has a consulting or advisory role for the following: Astellas Astra Zeneca Bayer BMS Cepheid Ferring Ipsen Jansen Lilly MSD Olympus Pfizer Pierre Fabre Roche Sanochemia Sanofi Takeda Urogen and Wolff. All remaining authors have declared no conflicts of interest.

非肌层浸润性膀胱癌 整块切除 经尿道膀胱肿瘤切除术 Meta分析

Adult Carotenoids Female Humans Lutein Male *Urinary Bladder Neoplasms/epidemiology/prevention & control Zeaxanthins beta Carotene bladder cancer blood diet lycopene zeaxanthin α-carotene β-carotene β-cryptoxanthin

Aged Aged 80 and over Female Humans Male Middle Aged Neoplasm Recurrence Local/*therapy Rhabdomyosarcoma/mortality/*therapy Survival Analysis Urinary Bladder Neoplasms/mortality/*therapy Adult Bladder Rhabdomyosarcoma

Carcinoma Transitional Cell/pathology Disease-Free Survival Humans *Neoplasm Staging Prognosis Urinary Bladder/*pathology Urinary Bladder Neoplasms/*pathology Bladder urothelial carcinoma Meta-analysis Squamous differentiation

Combined Modality Therapy Humans Light Narrow Band Imaging *Urinary Bladder Neoplasms/diagnostic imaging/surgery cystoscopy recurrence urinary bladder neoplasms

Her2 bladder cancer clinical significance meta-analysis prognostic value commercial or financial relationships that could be construed as a potential conflict of interest.

Animals *Cheese Cohort Studies Dairy Products Diet Humans Milk Risk Factors *Urinary Bladder Neoplasms/epidemiology/etiology Yogurt

Case-Control Studies Humans Male NAD(P)H Dehydrogenase (Quinone)/*genetics Polymorphism Single Nucleotide Prostatic Neoplasms/*genetics Urinary Bladder Neoplasms/*genetics NQO1 gene meta-analysis polymorphism prostatic neoplasms urinary bladder neoplasms

Humans Neoplasm Staging Retrospective Studies Sensitivity and Specificity Ultrasonography *Urinary Bladder Neoplasms/diagnostic imaging

Animals Body Mass Index Case-Control Studies Cohort Studies Dairy Products/*statistics & numerical data Diet/methods Educational Status Feeding Behavior Female Humans Male Milk/*statistics & numerical data Risk Factors Smoking/epidemiology Urinary Bladder Neoplasms/*epidemiology

alcohol bladder cancer dose-response meta-analysis systematic review commercial or financial relationships that could be construed as a potential conflict of interest.

*Carcinoma Transitional Cell/surgery Cystectomy/adverse effects Humans Neoplasm Recurrence Local *Urinary Bladder Neoplasms/surgery

Adult Female *Hormones/adverse effects Humans Menopause Middle Aged Prospective Studies *Reproductive History Risk Factors *Urinary Bladder Neoplasms/epidemiology Bladder cancer Health Study Nurses’ females hormones reproductive factors

Bcg Bladder cancer Covid-19 Coronavirus

Humans *Laser Therapy/adverse effects Neoplasm Invasiveness Treatment Outcome Urinary Bladder Neoplasms/pathology/*surgery

Antineoplastic Combined Chemotherapy Protocols/*therapeutic use Carcinoma Transitional Cell/*drug therapy/pathology Clinical Trials Phase II as Topic Clinical Trials Phase III as Topic Humans Neoplasm Metastasis Neoplasm Staging Practice Guidelines as Topic Randomized Controlled Trials as Topic Urinary Bladder Neoplasms/*drug therapy/pathology Immune checkpoint inhibitors Platinum-based chemotherapy Survival outcomes Treatment guidelines Urothelial carcinoma funded this work. MK PK and SD are employees of Evidera.